ULK1 promotes oxaliplatin resistance of colon cancer via phosphorylation of Bax S184 [0.03%]
ULK1通过磷酸化Bax S184促进奥沙利铂耐药性 colorectal cancer
Ze Rong,Jing Xing,Liangpei Wu et al.
Ze Rong et al.
Background: Oxaliplatin resistance continues to undermine therapeutic outcomes in colon cancer (CC). Recent investigations point to unc-51 like kinase 1 (ULK1)-mediated disruption of apoptotic pathways as a potential driv...
Response to 'Towards an individualized strategy in perioperative chemotherapy for pancreatic cancer' [0.03%]
对“胰腺癌围手术期化疗个体化策略”一文的回应
Thomas F Stoop,Y H Andrew Wu,Atsushi Oba et al.
Thomas F Stoop et al.
Expansion cohorts in phase 1 oncology trials: a systematic review of their design, implementation and outcomes [0.03%]
一期肿瘤试验中的扩展队列研究：系统评价其设计、实施和结果
Julio Herrero Colomina,Xinjie Hu,Habana Dinizulu et al.
Julio Herrero Colomina et al.
The urgent need for drug development for cancer patients and the complexity of novel therapies have led to the increasing importance of expansion cohorts (EC) within phase 1 trial design. We conducted a systematic review of oncology phase 1...
Pre-diagnostic circulating untargeted metabolomics and risk of overall and clinically significant prostate cancer: a systematic review and meta-analysis [0.03%]
循环未靶向代谢组学与前列腺癌风险的关系：系统评价和meta分析
Harriett Fuller,Orietta P Agasaro,Jim M Guevara et al.
Harriett Fuller et al.
Background: Metabolomic dysregulation contributes to prostate cancer (PCa) pathogenesis, and studies suggest that circulating metabolites have strong potential to act as clinical biomarkers. However, evidence of associati...
Myc-mediated epigenetic silencing of ACAP3 promotes lung adenocarcinoma proliferation via regulating EGFR dynamics [0.03%]
MYC介导的ACAP3表观遗传学沉默通过调节EGFR动力学促进肺腺癌增殖
Zhixiong Dong,Wenran Xie,Ningxin Zhang et al.
Zhixiong Dong et al.
Background: Despite significant advances in diagnosis and therapy, the prognosis of late-stage lung adenocarcinoma (LUAD) remains poor, underscoring the urgent need for effective biomarkers to enable early detection. Epig...
Functional footprints of homologous recombination deficiency in prostate cancer revealed by ctDNA fragmentation and transcription factor accessibility [0.03%]
基于ctDNA片段化和转录因子可及性揭示前列腺癌同源重组缺陷的功能表征
Georgios Vlachos,Tina Moser,Isaac Lazzeri et al.
Georgios Vlachos et al.
Background: Homologous recombination deficiency (HRD) is a predictive biomarker for response to PARP inhibitors and platinum-based therapies in prostate cancer (PCa). However, current diagnostic approaches, often limited ...
Alcohol consumption and mortality from four alcohol-related cancers in Australia 1950-2018: a time series analysis [0.03%]
1950年至2018年澳大利亚饮酒量与四种酒精相关癌症死亡率的时间序列分析
Heng Jiang,Michael Livingston,Robin Room et al.
Heng Jiang et al.
Background: Long-term alcohol use is a recognised risk factor for liver, upper aerodigestive tract (UADT), colorectal, and female breast cancers, yet aggregate-level evidence linking alcohol consumption to mortality from ...
Editorial Expression of Concern: Two novel human anti-ErbB2 immunoagents are active on trastuzumab-resistant tumours [0.03%]
关于两种新型人源抗ErbB2免疫制剂对赫赛汀耐药肿瘤有活性的社论表达关注
T Gelardi,V Damiano,R Rosa et al.
T Gelardi et al.
Prognostic model for pancreatic cancer based on machine learning of routine slides and transcriptomic tumor analysis [0.03%]
基于机器学习的常规胰腺癌病理切片和转录组分析的预后模型
Manabu Takamatsu,Mariko Tanaka,Yohei Masugi et al.
Manabu Takamatsu et al.
Background: Prognostication for pancreatic ductal adenocarcinoma (PDAC) using histologic images is difficult due to tumor heterogeneity. We developed an artificial intelligence (AI) model to predict postoperative recurren...
Diagnostic accuracy of combinatorial mRNA biomarkers for non-invasive detection and therapy monitoring of oral and oropharyngeal SCC [0.03%]
用于非侵入性检测和头颈鳞癌治疗监测的组合型mRNA生物标志物的诊断准确性
Leonie Hose,Alina Celine Tekin,Bart Verwaaijen et al.
Leonie Hose et al.
Background: Oral squamous cell carcinoma (OSCC) is increasingly common, with over 380,000 new cases annually. Despite its high incidence (6.0 per 100,000 males; 2.3 per 100,000 females) and poor prognosis, no molecular bi...